Detection of Minimal Residual Disease (MRD) is  becoming more important in different fields of hematology including Multiple Myeloma. Over the past decades we’ve been able to improve the sensitivity of detecting minimal levels of MRD through innovations in molecular biology. But should MRD always be treated?  Will it give a better outcome for the patient? And do the benefits outweigh the costs?”

Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Dr Fredrik Schjesvold, head of the Oslo Myeloma Center.

MAT-BE-2200983 (1.0) 12 2022